Edwards gains FDA OK for next-gen heart valve trial

08/6/2013 | MassDevice.com (Boston)

Edwards Lifesciences has received conditional investigational device exemption approval from the FDA to enroll as many as 500 inoperable and high-risk aortic stenosis patients in a clinical study of its Sapien 3 transcatheter aortic valve implantation device. The next-generation device improves on the older versions with advanced delivery systems, a lower profile and other features, a company official said.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN